Tweets
GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently.
@RheumNow #ACR22 #Plenary
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
#ACR22 Highlights. ILD in CTDs #rituximab = #cyclophoshamide at 6 mo for CTD ILD & ritux better on skin score in #scleroderma RECITAL RCT abst0003 but #pirfenidone added to #MMF not better than MMF alone in SLSIII RCT—ILD w #SSc abst#520 vs in SENCIS #nintedanib is + @RheumNow
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Great moderating PMR talk w/@SattuiSEMD this AM; phenomenal slides @drceowen re:imaging in PMR
Big ?s:
-Who needs this? All/some/many
-Which modality? Nice summary slide
-How to treat "subclinical" GCA (risk of overtreatment imo)
Ideas for next year?
#ACR22 @rheumnow #ACRBest https://t.co/akvsud3YVO
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
Preterm delivery and HTN disorders in #vasculitis
Abstract #0953 #ACR22 @RheumNow @StanfordRheum
🤰87 deliveries from 1991-2012
🤰Higher risk for preterm delivery (PTD) (RR 4), PPROM (RR 4), HTN dx of preg. (RR 3)
🤰Of spon. PTD, 17% born between 20-31 weeks
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology? #ACR22
https://t.co/TThsEQ7RDH https://t.co/ZHNlH3J0de
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Ab1676 #ACR22 SAPHYR: Sarilumab in Refractory PMR
52wk SAR 200 mg q2w + 14w taper GC v PBO+GC taper
Primary endpt: sustain response at 52w
Early term 2/2 COVID, 117 pt
SAR remission 28% vs PBO 10%, p=0.02
Data consistent when removes CRP data
PBO: more GCs 2/2 PMR flare
@Rheumnow https://t.co/kHq3juULX1
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
How much does diet and exercise help in knee osteoarthritis?
Pragmatic RCT (WE-CAN), n=823
a diet & exercise intervention program led to:
- 10kg weight loss
- some significant pain improvements
We need to fund diet & exercise programs for OA patients!
ABST1675 #ACR22 @RheumNow https://t.co/Ctm8ZoRF3o
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Update on ACR Guideline on Prevention and Treatment of GIOP.
Sequential Rx when initial OP Rx and GC discontinued
https://t.co/TWdI728pCp
Mary Beth Humphrey #ACR22 @RheumNow https://t.co/i320si4RJp
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
Sarilumab (IL-6R inhibitor) in phase 3 trial for relapsing PMR (SAPHYR trial).
Key inclusion: Disease flare while taking >7.5mg prednisolone
Sustained remission: resolution of symptoms, normalisation of CRP, adherence to prednisolone taper
@RheumNow #ACR22 #Plenary
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Spiera et al. Sarilumab in refractory PMR (SAPHYR) - Phase 3 RCT. Significant effect of IL-6i. @RheumNow #ACR22 Abstr#1676 https://t.co/2MS441B8gU https://t.co/jBd7YJKrTs
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better than no MTX. Will change my practice - if I can access to a #peguricase, I will Rx w concomitant MTX Abst#0001 #ACR22 @RheumNow
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Updated ACR Guidelines on Prevention and Rx of GIOP
Rx recommendations when new fractures occur after 12 months of initial OP Rx
https://t.co/TWdI728pCp
Mary Beth Humphrey #ACR22 @RheumNow https://t.co/wHANvymd5R
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
